These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36366390)

  • 1. Adjuvant Treatment for Breast Cancer Patients Using Individualized Neoantigen Peptide Vaccination-A Retrospective Observation.
    Zelba H; McQueeney A; Rabsteyn A; Bartsch O; Kyzirakos C; Kayser S; Harter J; Latzer P; Hadaschik D; Battke F; Hartkopf AD; Biskup S
    Vaccines (Basel); 2022 Nov; 10(11):. PubMed ID: 36366390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case Report: Targeting of individual somatic tumor mutations by multipeptide vaccination tailored for HLA class I and II presentation induces strong CD4 and CD8 T-cell responses in a patient with metastatic castration sensitive prostate cancer.
    Zelba H; Rabsteyn A; Bartsch O; Kyzirakos C; Kayser S; Seibold M; Harter J; Latzer P; Hadaschik D; Battke F; Golf A; Rettig MB; Biskup S
    Front Immunol; 2023; 14():1271449. PubMed ID: 37920460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion.
    Cai Z; Su X; Qiu L; Li Z; Li X; Dong X; Wei F; Zhou Y; Luo L; Chen G; Chen H; Wang Y; Zeng Y; Liu X
    Mol Cancer; 2021 Dec; 20(1):164. PubMed ID: 34903219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites.
    Morisaki T; Hikichi T; Onishi H; Morisaki T; Kubo M; Hirano T; Yoshimura S; Kiyotani K; Nakamura Y
    Immunol Invest; 2021 Jul; 50(5):562-579. PubMed ID: 32660279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune monitoring and TCR sequencing of CD4 T cells in a long term responsive patient with metastasized pancreatic ductal carcinoma treated with individualized, neoepitope-derived multipeptide vaccines: a case report.
    Sonntag K; Hashimoto H; Eyrich M; Menzel M; Schubach M; Döcker D; Battke F; Courage C; Lambertz H; Handgretinger R; Biskup S; Schilbach K
    J Transl Med; 2018 Feb; 16(1):23. PubMed ID: 29409514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Case Report: Long-Term Survival of a Patient with Cerebral Metastasized Ovarian Carcinoma Treated with a Personalized Peptide Vaccine and Anti-PD-1 Therapy.
    Zelba H; Kyzirakos C; Kayser S; Shao B; Reinhardt A; Pieper N; Rabsteyn A; Döcker D; Armeanu-Ebinger S; Kloor M; Hadaschik D; Schulze M; Battke F; Golf A; Biskup S
    Vaccines (Basel); 2024 Apr; 12(4):. PubMed ID: 38675779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination treatment of radiofrequency ablation and peptide neoantigen vaccination: Promising modality for future cancer immunotherapy.
    Shou J; Mo F; Zhang S; Lu L; Han N; Liu L; Qiu M; Li H; Han W; Ma D; Guo X; Guo Q; Huang Q; Zhang X; Ye S; Pan H; Chen S; Fang Y
    Front Immunol; 2022; 13():1000681. PubMed ID: 36248865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Neoantigen-Based Peptide Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard Treatment.
    Chen Z; Zhang S; Han N; Jiang J; Xu Y; Ma D; Lu L; Guo X; Qiu M; Huang Q; Wang H; Mo F; Chen S; Yang L
    Front Immunol; 2021; 12():691605. PubMed ID: 34484187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma.
    Mørk SK; Kadivar M; Bol KF; Draghi A; Westergaard MCW; Skadborg SK; Overgaard N; Sørensen AB; Rasmussen IS; Andreasen LV; Yde CW; Trolle T; Garde C; Friis-Nielsen J; Nørgaard N; Christensen D; Kringelum JV; Donia M; Hadrup SR; Svane IM
    Oncoimmunology; 2022; 11(1):2023255. PubMed ID: 35036074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefits of an Immunogenic Personalized Neoantigen Nanovaccine in Patients with High-Risk Gastric/Gastroesophageal Junction Cancer.
    Liu Q; Chu Y; Shao J; Qian H; Yang J; Sha H; Cen L; Tian M; Xu Q; Chen F; Yang Y; Wang W; Wang K; Yu L; Wei J; Liu B
    Adv Sci (Weinh); 2022 Nov; 10(1):e2203298. PubMed ID: 36351249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose IL-2/CD25 fusion protein amplifies vaccine-induced CD4
    Hernandez R; LaPorte KM; Hsiung S; Santos Savio A; Malek TR
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34475132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens.
    Linette GP; Becker-Hapak M; Skidmore ZL; Baroja ML; Xu C; Hundal J; Spencer DH; Fu W; Cummins C; Robnett M; Kaabinejadian S; Hildebrand WH; Magrini V; Demeter R; Krupnick AS; Griffith OL; Griffith M; Mardis ER; Carreno BM
    Proc Natl Acad Sci U S A; 2019 Nov; 116(47):23662-23670. PubMed ID: 31685621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives.
    Chen X; Yang J; Wang L; Liu B
    Theranostics; 2020; 10(13):6011-6023. PubMed ID: 32483434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoantigen-reactive T cells exhibit effective anti-tumor activity against colorectal cancer.
    Yu Y; Zhang J; Ni L; Zhu Y; Yu H; Teng Y; Lin L; Xue Z; Xue X; Shen X; Song H; Su X; Sun W; Cai Z
    Hum Vaccin Immunother; 2022 Dec; 18(1):1-11. PubMed ID: 33689574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Personalized neoantigen vaccines: A new approach to cancer immunotherapy.
    Aldous AR; Dong JZ
    Bioorg Med Chem; 2018 Jun; 26(10):2842-2849. PubMed ID: 29111369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The present status and future prospects of peptide-based cancer vaccines.
    Hirayama M; Nishimura Y
    Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Broadening CD4
    Filskov J; Mikkelsen M; Hansen PR; Christensen JP; Thomsen AR; Andersen P; Bukh J; Agger EM
    J Virol; 2017 Jul; 91(14):. PubMed ID: 28446674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond Sequencing: Prioritizing and Delivering Neoantigens for Cancer Vaccines.
    Roesler AS; Anderson KS
    Methods Mol Biol; 2022; 2410():649-670. PubMed ID: 34914074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients.
    Takahashi R; Toh U; Iwakuma N; Takenaka M; Otsuka H; Furukawa M; Fujii T; Seki N; Kawahara A; Kage M; Matsueda S; Akagi Y; Yamada A; Itoh K; Sasada T
    Breast Cancer Res; 2014 Jul; 16(4):R70. PubMed ID: 24992895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
    Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
    J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.